| Mark S Lantz, MD | |
|
3300 Oakdale Ave N, Robbinsdale, MN 55422-2926 | |
| (763) 520-5370 | |
| Not Available |
| Full Name | Mark S Lantz |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 34 Years |
| Location | 3300 Oakdale Ave N, Robbinsdale, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063466936 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 36602 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Francis Regional Medical Center | Shakopee, MN | Hospital |
| Allina United Hospital | Saint paul, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Metropolitan Anesthesia Network Llp | 5698689123 | 647 |
News Archive
Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.
Low birth weight infants are host to numerous microorganisms immediately after birth, and the microbiomes of their mouths and gut start out very similar but differentiate significantly by day 15 according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.
EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.
OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.
› Verified 1 days ago
| Entity Name | Metropolitan Anesthesia Network Llp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558314427 PECOS PAC ID: 5698689123 Enrollment ID: O20031118000579 |
News Archive
Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.
Low birth weight infants are host to numerous microorganisms immediately after birth, and the microbiomes of their mouths and gut start out very similar but differentiate significantly by day 15 according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.
EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.
OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.
› Verified 1 days ago
| Entity Name | Anesthesiology, P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013960798 PECOS PAC ID: 9335033034 Enrollment ID: O20040212000459 |
News Archive
Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.
Low birth weight infants are host to numerous microorganisms immediately after birth, and the microbiomes of their mouths and gut start out very similar but differentiate significantly by day 15 according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.
EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.
OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark S Lantz, MD 14700 28th Ave N, Suite 20, Plymouth, MN 55447-4835 Ph: (763) 559-3779 | Mark S Lantz, MD 3300 Oakdale Ave N, Robbinsdale, MN 55422-2926 Ph: (763) 520-5370 |
News Archive
Like a circuit breaker that prevents electrical wiring from overheating and bringing down the house, a tiny family of three molecules stops the immune system from mounting an out-of-control, destructive inflammatory response against invading pathogens, researchers at the Salk Institute for Biological Studies have found.
Low birth weight infants are host to numerous microorganisms immediately after birth, and the microbiomes of their mouths and gut start out very similar but differentiate significantly by day 15 according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.
EKOS Corporation today announced the launch of two more landmark clinical studies named SEATTLE I & II, intended to further establish the safety and efficacy of its unique, ultrasound-accelerated thrombolysis in treating patients with life-threatening pulmonary embolism.
OrbusNeich today announced that six-month clinical follow-up data show the safety and efficacy of the combination of pre-dilatation with a paclitaxel drug-eluting balloon (Sequent Please®, B.Braun) followed by implantation of the company's Genous Bio-engineered R stent for the percutaneous treatment of coronary artery stenosis.
› Verified 1 days ago
William G Atmore, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5370 | |
Nilesh Jambhekar, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-581-2771 | |
Michael J Tully, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5370 | |
Andrew J Houlton, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5370 | |
Thomas E Wright, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5370 | |
Bryan J Walker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3300 Oakdale Ave N, Robbinsdale, MN 55422 Phone: 763-520-5370 |